Proteomic and phosphoproteomic measurements enhance ability to predict ex vivo drug response in AML.

ABSTRACT: Acute Myeloid Leukemia (AML) affects 20,000 patients in the US annually with a five-year survival rate of approximately 25%. One reason for the low survival rate is the high prevalence of clonal evolution that gives rise to heterogeneous sub-populations of leukemic cells with diverse mutation spectra, which eventually leads to disease relapse. This genetic heterogeneity drives the activation of complex signaling pathways that is reflected at the protein level. This diversity makes it difficult to treat AML with targeted therapy, requiring custom patient treatment protocols tailored to each individual's leukemia. Toward this end, the Beat AML research program prospectively collected genomic and transcriptomic data from over 1000 AML patients and carried out ex vivo drug sensitivity assays t

SUBMITTER: Gosline SJC 

PROVIDER: S-EPMC9327422 | biostudies-literature | 2022 Jul

REPOSITORIES: biostudies-literature